+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Cholesterol Lowering Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027

  • ID: 5005252
  • Report
  • January 2020
  • Region: Global
  • 196 Pages
  • Transparency Market Research
1 of 3

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • AbbVie, Inc.
  • Amgen, Inc.
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Mylan N.V.
  • Novartis AG
  • MORE
Cholesterol Lowering Drugs Market – Scope of the Report

This report on the global cholesterol lowering drugs market studies past as well as current growth trends and opportunities to gain valuable insights of the same indicators for the said market during the forecast period from 2019 to 2027. The report provides the overall market revenue of the cholesterol lowering drugs market for the period of 2017–2027, with 2018 as the base year and 2027 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the cholesterol lowering drugs market for the forecast period.

The report has been prepared after an extensive primary and secondary research. Primary research involves bulk of research efforts, wherein, analysts carry out interviews with key opinion leaders, industry leaders, and opinion makers. Extensive secondary research involves referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the cholesterol lowering drugs market.

Secondary research also includes Internet sources, statistical data from government agencies, websites, and trade associations. Analysts have employed a combination of top-down and bottom-up approach to study various phenomena in the cholesterol lowering drugs market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments and sub-segments included in the scope of the study. Furthermore, the report sheds light on changing competitive dynamics in the cholesterol lowering drugs market. These indices serve as valuable tools for existing market players as well as for entities interested in participating in the cholesterol lowering drugs market.

The report delves into the competitive landscape of the cholesterol lowering drugs market. Key players operating in the cholesterol lowering drugs market have been identified, and each one of them has been profiled for their distinguishing business attributes. Company overview, financial standings, recent developments, and SWOTs are some of the attributes of players in the cholesterol lowering drugs market that have been profiled in this report.

Key Questions Answered
  • What is the sales/revenue generated by each drug class segment of the cholesterol lowering drugs market across all regions during the forecast period?
  • What are the opportunities in the cholesterol lowering drugs market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which region is likely to expand at the fastest CAGR during the forecast period?
  • Which cholesterol lowering drugs class, indication, and distribution channel segments are expected to generate maximum revenue globally in 2027? Which segment is projected to expand at the highest CAGR during the forecast period?
  • What was the market share or position of different companies operating in the global market in 2018?
Research Objectives and Research Approach

The comprehensive report on the cholesterol lowering drugs market begins with an overview of the said market, followed by the scope and objectives of this study. Following this, the report provides detailed explanation of the objectives behind this study, pipeline analysis, key brand sales analysis, key merger & acquisition, and disease prevalence rate of different diseases and conditions.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into small sections. The entire report comprises an exhaustive collection of graphs and tables appropriately interspersed in the entire compilation. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the cholesterol lowering drugs market, in terms of drug class, indication, distribution channel, and region. Key segments under each criteria have been studied at length, and the market share for each of them at the end of 2027 has been provided herein. Such valuable insights enable market stakeholders in making informed business decisions for investment in the cholesterol lowering drugs market.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AbbVie, Inc.
  • Amgen, Inc.
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Mylan N.V.
  • Novartis AG
  • MORE

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Cholesterol Lowering Drugs Market

4. Market Overview
4.1. Introduction
4.1.1. Drug Class Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Cholesterol Lowering Drugs Market Analysis and Forecasts, 2017–2027

5. Market Outlook
5.1. Pipeline Analysis
5.2. Key Drug Brand Analysis
5.3. Key Merger & Acquisitions
5.4. Pipeline Analysis
5.5. Global Prevalence of Cardiovascular Diseases

6. Global Cholesterol Lowering Drugs Market Analysis and Forecasts, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Drug Class, 2017–2027
6.3.1. Statins and Combination
6.3.2. PCSK9 Inhibitors
6.3.3. Bile Acid Sequestrants
6.3.4. Fibrates
6.3.5. Cholesterol Absorption Inhibitors
6.3.6. Others
6.4. Market Attractiveness, by Drug Class

7. Global Cholesterol Lowering Drugs Market Analysis and Forecasts, by Indication
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Indication, 2017–2027
7.3.1. Hypercholesterolemia
7.3.2. Coronary Artery Disease
7.3.3. Higher Triglycerides
7.4. Market Attractiveness, by Indication

8. Global Cholesterol Lowering Drugs Market Analysis and Forecasts, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Distribution Channel, 2017–2027
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Online Pharmacies
8.4. Market Attractiveness, by Distribution Channel

9. Global Cholesterol Lowering Drugs Market Analysis and Forecasts, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness, by Region

10. North America Cholesterol Lowering Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Drug Class, 2017–2027
10.2.1. Statins and Combination
10.2.2. PCSK9 Inhibitors
10.2.3. Bile Acid Sequestrants
10.2.4. Fibrates
10.2.5. Cholesterol Absorption Inhibitors
10.2.6. Others
10.3. Market Value Forecast, by Indication, 2017–2027
10.3.1. Hypercholesterolemia
10.3.2. Coronary Artery Disease
10.3.3. Higher Triglycerides
10.4. Market Value Forecast, by Distribution Channel, 2017–2027
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.5. Market Value Forecast, by Country, 2017–2027
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Drug Class
10.6.2. By Indication
10.6.3. By Distribution Channel
10.6.4. By Country

11. Europe Cholesterol Lowering Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Drug Class, 2017–2027
11.2.1. Statins and Combination
11.2.2. PCSK9 Inhibitors
11.2.3. Bile Acid Sequestrants
11.2.4. Fibrates
11.2.5. Cholesterol Absorption Inhibitors
11.2.6. Others
11.3. Market Value Forecast, by Indication, 2017–2027
11.3.1. Hypercholesterolemia
11.3.2. Coronary Artery Disease
11.3.3. Higher Triglycerides
11.4. Market Value Forecast, by Distribution Channel, 2017–2027
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.5. Market Value Forecast, by Country/Sub-region, 2017–2027
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Drug Class
11.6.2. By Indication
11.6.3. By Distribution Channel
11.6.4. By Country/Sub-region

12. Asia Pacific Cholesterol Lowering Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Drug Class, 2017–2027
12.2.1. Statins and Combination
12.2.2. PCSK9 Inhibitors
12.2.3. Bile Acid Sequestrants
12.2.4. Fibrates
12.2.5. Cholesterol Absorption Inhibitors
12.2.6. Others
12.3. Market Value Forecast, by Indication, 2017–2027
12.3.1. Hypercholesterolemia
12.3.2. Coronary Artery Disease
12.3.3. Higher Triglycerides
12.4. Market Value Forecast, by Distribution Channel, 2017–2027
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5. Market Value Forecast, by Country/Sub-region, 2017–2027
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Drug Class
12.6.2. By Indication
12.6.3. By Distribution Channel
12.6.4. By Country/Sub-region

13. Latin America Cholesterol Lowering Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Drug Class, 2017–2027
13.2.1. Statins and Combination
13.2.2. PCSK9 Inhibitors
13.2.3. Bile Acid Sequestrants
13.2.4. Fibrates
13.2.5. Cholesterol Absorption Inhibitors
13.2.6. Others
13.3. Market Value Forecast, by Indication, 2017–2027
13.3.1. Hypercholesterolemia
13.3.2. Coronary Artery Disease
13.3.3. Higher Triglycerides
13.4. Market Value Forecast, by Distribution Channel, 2017–2027
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5. Market Value Forecast, by Country/Sub-region, 2017–2027
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Drug Class
13.6.2. By Indication
13.6.3. By Distribution Channel
13.6.4. By Country/Sub-region

14. Middle East & Africa Cholesterol Lowering Drugs Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Drug Class, 2017–2027
14.2.1. Statins and Combination
14.2.2. PCSK9 Inhibitors
14.2.3. Bile Acid Sequestrants
14.2.4. Fibrates
14.2.5. Cholesterol Absorption Inhibitors
14.2.6. Others
14.3. Market Value Forecast, by Indication, 2017–2027
14.3.1. Hypercholesterolemia
14.3.2. Coronary Artery Disease
14.3.3. Higher Triglycerides
14.4. Market Value Forecast, by Distribution Channel, 2017–2027
14.4.1. Hospital Pharmacies
14.4.2. Retail Pharmacies
14.4.3. Online Pharmacies
14.5. Market Value Forecast, by Country/Sub-region, 2017–2027
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Drug Class
14.6.2. By Indication
14.6.3. By Distribution Channel
14.6.4. By Country/Sub-region

15. Competition Landscape
15.1. Market Player – Competition Matrix (By Tier and Size of companies)
15.2. Market Share Analysis/Ranking, by Company (2018)
15.3. Company Profiles
15.3.1. Pfizer Inc.
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Company Financials
15.3.1.3. Growth Strategies
15.3.1.4. SWOT Analysis
15.3.2. Sanofi
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Company Financials
15.3.2.3. Growth Strategies
15.3.2.4. SWOT Analysis
15.3.3. GlaxoSmithKline plc
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Company Financials
15.3.3.3. Growth Strategies
15.3.3.4. SWOT Analysis
15.3.4. Novartis AG
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Company Financials
15.3.4.3. Growth Strategies
15.3.4.4. SWOT Analysis
15.3.5. Merck & Co., Inc.
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Company Financials
15.3.5.3. Growth Strategies
15.3.5.4. SWOT Analysis
15.3.6. Amgen, Inc.
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Company Financials
15.3.6.3. Growth Strategies
15.3.6.4. SWOT Analysis
15.3.7. Takeda Pharmaceutical Company Limited
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Company Financials
15.3.7.3. Growth Strategies
15.3.7.4. SWOT Analysis
15.3.8. Sun Pharmaceutical Industries Ltd.
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Company Financials
15.3.8.3. Growth Strategies
15.3.8.4. SWOT Analysis
15.3.9. AbbVie, Inc.
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Company Financials
15.3.9.3. Growth Strategies
15.3.9.4. SWOT Analysis
15.3.10. Mylan N.V.
15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.10.2. Company Financials
15.3.10.3. Growth Strategies
15.3.10.4. SWOT Analysis

Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Pfizer Inc.
  • Sanofi
  • GlaxoSmithKline plc
  • Novartis AG
  • Merck & Co., Inc.
  • Amgen, Inc.
  • Takeda Pharmaceutical Company Limited
  • Sun Pharmaceutical Industries Ltd.
  • AbbVie, Inc.
  • Mylan N.V.
Note: Product cover images may vary from those shown
Adroll
adroll